Alpelisib Plus Fulvestrant in PIK3CA -Altered and PIK3CA -Wild-Type Estrogen Receptor–Positive Breast Cancer

This phase 1b clinical trial evaluates the dose response and safety of alpelisib plus fulvestrant treatment in women with advanced breast cancer.

https://ift.tt/2BhF4gz